HSBC Holdings’s BeOne Medicines Ltd ONC Stock Holding History

HSBC Holdings’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-18,288	Closed	-$2.56M	–	2927
2018 Q4	$2.56M	Buy	+18,288	New	+$2.43M	﹤0.01%	1396

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HSBC Holdings's ONC Position: Q2 2026 in Review

HSBC Holdings sold out of BeOne Medicines Ltd (ONC) in Q2 2026, closing a stake of 707 shares — an estimated $208K sold.

HSBC Holdings first reported a position in ONC in Q3 2016 and held it in 35 quarters. The position peaked at $453M in Q3 2018. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

HSBC Holdings reported no remaining BeOne Medicines Ltd position as of Q2 2026 after selling out during the quarter.
HSBC Holdings sold 707 BeOne Medicines Ltd shares in Q2 2026, an estimated $208K.
HSBC Holdings first reported a position in BeOne Medicines Ltd in Q3 2016 and held it in 35 quarters.
HSBC Holdings's BeOne Medicines Ltd position peaked at $453M in Q3 2018.
283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.